Drug intelligence / Profile preview

Moximer

Development stage
Unknown
Lead developer
Martia Laboratories
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Moximer is a preservative-free ophthalmic solution containing 0.5% w/v moxifloxacin, developed and marketed by Martia Laboratories for the treatment of bacterial eye infections, such as bacterial conjunctivitis. As a fourth-generation fluoroquinolone antibiotic, moxifloxacin exerts its bactericidal effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. This dual mechanism of action helps prevent the development of resistance. The product is specifically formulated for topical ophthalmic administration and is available in the Indian market as a 5 ml eye drop formulation.

Brand names
Moximer
Other names
moxifloxacin 0.5% ophthalmic solutionmoxifloxacin 0.5% eye drops
02

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on Moximer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moximer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call